Literature DB >> 10891449

Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.

P M Newman1, B H Chong.   

Abstract

Immune heparin-induced thrombocytopenia (HIT) is associated with antibodies directed against a complex of platelet factor 4 (PF4) and heparin. We were able to affinity purify anti-PF4-heparin IgG (HIT IgG) from the plasma of 2 patients with HIT. Under conditions that were more physiological and sensitive than those in previous studies, we observed that this HIT IgG caused platelet aggregation on the addition of heparin. Platelets activated with HIT IgG increased their release and surface expression of PF4. We quantitated, for the first time, the binding of affinity-purified HIT iodine 125-IgG to platelets as they activated in a plasma milieu. Binding of the HIT IgG was dependent on heparin and required some degree of platelet activation. Blocking the platelet FcgammaRII with the monoclonal antibody IV.3 did not prevent HIT IgG binding to activated platelets. We concluded that anti-PF4-heparin IgG is the component in these HIT plasmas that induces platelet aggregation. The Fab region of HIT IgG binds to PF4-heparin on the surface of activated platelets. We propose that only then does the Fc portion of the bound IgG further activate the same or adjacent platelets through the Fc receptor. Our data support a dynamic model of platelet activation in which released PF4 enhances further antibody binding and more release.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891449

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Jessica D Hirsch; Teshell K Greene; Li Zhai; Vincent M Hayes; M Anna Kowalska; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

Review 2.  Thrombin inhibitors and cardiopulmonary bypass.

Authors:  Alan Merry
Journal:  J Extra Corpor Technol       Date:  2006-03

3.  Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.

Authors:  Todd Golden; Sehem Ghazala; Rita Wadeea; Shilpa Junna
Journal:  BMJ Case Rep       Date:  2017-07-14

4.  Heparin-induced thrombocytopenia: overview and treatment.

Authors:  Daniel A Zinkovsky; Marilena S Antonopoulos
Journal:  P T       Date:  2008-11

5.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Authors:  Lubica Rauova; Li Zhai; M Anna Kowalska; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

6.  Prevention of Collagen-Induced Platelet Binding and Activation by Thermosensitive Nanoparticles.

Authors:  James McMasters; Alyssa Panitch
Journal:  AAPS J       Date:  2015-06-13       Impact factor: 4.009

7.  Hats Off to HIT: A Case Report.

Authors:  Akhwand Shakeel Ahmad; Dhia Jaber Al-Layla; Manjula Dhinakar
Journal:  Oman Med J       Date:  2012-05

8.  Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

9.  CD32a antibodies induce thrombocytopenia and type II hypersensitivity reactions in FCGR2A mice.

Authors:  Todd Meyer; Liza Robles-Carrillo; Monica Davila; Meghan Brodie; Hina Desai; Mildred Rivera-Amaya; John L Francis; Ali Amirkhosravi
Journal:  Blood       Date:  2015-09-22       Impact factor: 22.113

Review 10.  Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

Authors:  David F Pinelli; Mandy L Ford
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.